Lixisenatide Reduces Motor Disability Progression in Parkinson Disease
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.